miR-126 plays an important role in the proliferation, invasion, migration, and chemotherapeutics resistance in cancer. Epigallocatechin-3-gallate (EGCG), as the major polyphenolic constituent present in green tea, is a promising anticancer agent. However, the role of miR-126 in EGCG anticancer remains unclear. Here, we investigated the effects of miR-126 and EGCG on cell viability, apoptosis, cell cycle distribution of osteosarcoma cells and the sensitization of miR-126 on osteosarcoma cells to EGCG.
Methods
The cell viability, apoptosis and cycle distribution were analyzed using MTT assay and flow cytometry.
Results
Our results showed that EGCG (0.025, 0.05, 0.1, 0.2 g/L) suppresses proliferation of osteosarcoma MG63 and U2OS cells in a concentration-dependent and time-dependent manner and the inhibitory effects of 0.05 g/L EGCG on U2OS cells were roughly equivalent to 20 μM cisplatin (DDP); miR-126 could promote apoptosis and inhibit proliferation in U2OS cells but without significant effects on cell cycle G1 phase arrest; EGCG suppressed proliferation of U2OS cells through induction of cell cycle G1 arrest and apoptotic death; overexpression of miR-126 enhanced the inhibitory effects of EGCG on proliferation in U2OS cells via promotion of apoptosis.
Conclusions
Our results demonstrate that enhanced expression of miR-126 increased the sensitivity of osteosarcoma cells to EGCG through induction of apoptosis.
The online version of this article (doi:10.1186/1477-7819-12-383) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CT designed the study and drafted the manuscript. LJ and AH did the experiments. XH and LJ collected and analyzed the data. All authors read and approved the final manuscript.
Osteosarcoma is a primary malignant bone tumor with high morbidity that occurs mainly in children and adolescents. Multiple options for the treatment of osteosarcoma have been described, including chemotherapy, radiation, and so on, however, therapeutic efficacy is typically transient and mostly absent with advanced disease[1]. Therefore, the need for more rational approaches to osteosarcoma therapy is essential.
Epigallocatechin-3-gallate (EGCG) is the most abundant catechin in green tea, showing anti-inflammatory, antioxidant, anticancer and immunomodulatory activities[2‐5]. It has been shown that EGCG has extensive anticancer activities, including in breast cancer[6], cervical cancer[7], lung cancer[8], prostate cancer[9], colon cancer[10], head and neck cancer[11], gastric cancer[12], ovarian cancer[13], even cancer stem cells[14], and so on. It was reported that combined administration of EGCG and interleukin 1 (IL-1) receptor antagonist could efficiently decrease IL-1-induced tumorigenic factors, leading to reduction in angiogenesis and invasiveness in human osteosarcoma cells[15]. It suggests that a combination of EGCG and interfering approaches against factors that play a crucial role in tumor progression is a promising strategy for improving therapeutic efficacy, including osteosarcoma.
Anzeige
MicroRNAs (miRs), a class of 22-nucleotide noncoding RNAs, have emerged as critical components of gene-regulatory networks controlling numerous important pathophysiological processes, including the initiation and progression of tumors. Studies on miRs have opened new avenues for both the diagnosis and treatment of cancer. Many miRs,[16‐18] including miR-126[19], are found to be involved in the proliferation, invasion, migration, and drug resistance[20] in osteosarcoma cells. It was found that miR-126 was consistently underexpressed in osteosarcoma tissues and cell lines and functioned as a tumor suppressor in osteosarcoma[19]. Studies showed that miR-126 could enhance the sensitivity of lung cancer[21] and cervical cancer[22] cells to anticancer agents. However, whether miR-126 can sensitize osteosarcoma cells to EGCG remains to be elucidated.
In this study, the effects of miR-126 and EGCG on the proliferation, apoptosis and cell cycle in osteosarcoma cells were investigated. Our results showed that miR-126 could enhance the sensitivity of osteosarcoma U2OS cells to EGCG, providing novel approaches or targets for reducing drug resistance in cancer.
Methods
Cell culture and stimulation
MG63 and U2OS cell lines (American Type Culture Collection (ATCC), USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) culture medium at 5% CO2. Cells were treated with EGCG (0.025, 0.05, 0.1, 0.2 g/L) for 24, 48 and 72 hours, or EGCG (0.05 g/L), cisplatin (DDP, 20 μM) or rapamycin (RAPA, 100 nm) for 48 hours as indicated. To investigate the roles of miR-126 in U2OS cells, the lentiviral vectors comprising pre-miR-126 or anti-miR-126 were constructed and used to infect U2OS cells, establishing stable U2OS cell lines overexpressing or silencing miR-126.
Cell proliferation assay
Cells treated with indicated reagents or samples in exponential growth were plated at a final concentration of 2 × 103 cells per well in 96-well plates. The viability of cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after 24, 48 and 72 hours of seeding. The optical density at 570 nm (OD570) of each well was measured with an enzyme-linked immunosorbent assay (ELISA) reader (ELX-800 type, BioTek Winooski, VT, USA).
Anzeige
Cell apoptosis assay
After being incubated in the presence of EGCG or RAPA for 48 hours, cells were harvested and treated with fluorescein isothiocyanate (FITC, BioVision, Mountain View, CA, USA) according to the manufacturer’s instructions. Cell apoptosis was detected by analyzing Annexin V-FITC binding by flow cytometry (Ex = 488 nm; Em = 530 nm) using a FITC signal detector and a propidium iodide (PI) signal detector.
Cell cycle analysis
The cells were digested with trypsin (Auragene Bioscience Corporation, Changsha, China) and collected after treatment for 48 hours, and washed with phosphate-buffered saline (PBS) twice. The cells were resuspended in PBS and then fixed in 70% ethanol at 4°C for 18 hours. The cells were washed with PBS and resuspended in Staining Solution (50 μg/mL of PI, 1 mg/mL of RNase A, 0.1% Triton X-100 in PBS). The stained cells (1 × 105) were then analyzed with a flow cytometer (Beckman Coulter, Brea, CA, USA).
Statistical analysis
Data were expressed as mean ± standard deviation (SD) from at least three separate experiments. Statistical analysis was carried out using SPSS 15.0 software (SPSS Inc, Chicago, IL, USA). The difference between two groups was analyzed by the Student’s t test. A value of P <0.05 was considered statistically significant.
Results
EGCG inhibits proliferation of osteosarcoma cells
To investigate the effects of EGCG on proliferation of osteosarcoma cells, the human osteosarcoma U2OS and MG63 cells were treated with different concentrations (0.025, 0.05, 0.1, 0.2 g/L) of EGCG for 24, 48, or 72 hours, respectively. The MTT results showed that the relative inhibitory rate of EGCG on U2OS and MG63 cells increased with enhancement of its treatment concentration and time. It suggests that EGCG suppresses proliferation of osteosarcoma cells in a concentration-dependent and time-dependent manner.
Overexpression of miR-126 augments EGCG inhibiting proliferation of osteosarcoma cells
As showed in Figure 1C, overexpression of miR-126 decreased cell viability in U2OS cells, indicating that miR-126 serves as a suppressor in osteosarcoma cells. Moreover, RAPA, as the inhibitor of the mammalian target of rapamycin (mTOR) pathway, could not affect miR-126 inhibition of proliferation of U2OS cells, suggesting that the role of miR-126 in osteosarcoma is not dependent on the mTOR pathway.
MTT assay showed that both DDP and EGCG could significantly inhibit the proliferation of osteosarcoma U2OS cells. The inhibitory effects of 0.05 g/L EGCG on U2OS cells were roughly equivalent to 20 μM DDP. Moreover, overexpression of miR-126 significantly decreased cell viability in U2OS cells treated with ECGC compared with ECGC treatment alone or combination of inhibition of miR-126 and ECGC treatment (Figure 1C).
Figure 1
Effect of EGCG and miR-126 on proliferation in osteosarcoma cells. The relative inhibitory rate of EGCG on osteosarcoma MG63 (A) and U2OS (B) cells (C) The cell viability in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG at indicated concentration. *P <0.05 vs. indicated group; aP <0.05 vs. Con alone group; bP <0.05 vs. anti-miR-126 alone group; cP <0.05 vs. pre-miR-126 alone group. Con, control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; RAPA, rapamycin.
×
Overexpression of miR-126 enhances EGCG induction of apoptosis in osteosarcoma cells
Flow cytometry results showed that overexpression of miR-126 could increase the apoptotic rate of osteosarcoma U2OS cells. Inhibition of miR-126 could decrease the apoptotic rate of osteosarcoma U2OS cells. The apoptosis in osteosarcoma U2OS cells induced by EGCG (0.05 g/L) was higher than that in control or overexpression of miR-126 alone group. Overexpression of miR-126 significantly enhanced EGCG-induced apoptosis in osteosarcoma U2OS cells and inhibition of miR-126 reduced EGCG-induced apoptosis in osteosarcoma U2OS cells (Figure 2).
To investigate whether the mTOR pathway is involved in miR-126 regulation of apoptosis in osteosarcoma U2OS cells, its inhibitor RAPA was used. The results showed that RAPA could not affect the apoptotic rate induced by miR-126 in U2OS cells, suggesting that the mTOR pathway is not involved in miR-126 promotion of apoptosis in osteosarcoma U2OS cells (Figure 2).
Figure 2
Effect of EGCG and miR-126 on apoptosis in osteosarcoma cells. (A) The representative images of flow cytometry analysis using Annexin V and PI staining. (B) The apoptotic rate in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG. *P <0.05 vs. indicated group; aP <0.05 vs. Con alone group; bP <0.05 vs. anti-miR-126 alone group; cP <0.05 vs. pre-miR-126 alone group. Con, control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; PI, propidium iodide; RAPA, rapamycin.
×
Anzeige
EGCG induces G1 phase arrest in osteosarcoma cells
As showed in Figure 3, overexpression of miR-126 or inhibition of miR-126 by anti-miR-126 did not have marked effects on the cell cycle G1 phase proportion in U2OS cells. And EGCG significantly increased the G1 proportion in U2OS cells and this action was not interfered by overexpression of miR-126 or inhibition of miR-126. Moreover, the ratios of G1 to S in U2OS cells were 2.8 in control, 4.8 in the pre-miR-126 group, 2.2 in the anti-miR-126 group, 26.2 in the EGCG group, 32.8 in the pre-miR-126 + EGCG group, and 32.0 in the anti-miR-126 + EGCG group. These data suggest EGCG may suppress G1/S transition in osteosarcoma cells, resulting in cell cycle G1 phase arrest, and this process is not affected by miR-126. In addition, our results also showed that combination of RAPA and miR-126 or anti-miR-126 did not affect the cell cycle G1 phase proportion in U2OS cells.
Figure 3
Effect of EGCG and miR-126 on cell cycle in osteosarcoma cells. (A) The representative images of flow cytometry analysis using PI staining. (B) The cell cycle distribution in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG. *P <0.05 vs. indicated group; aP <0.05 vs. Con alone group; bP <0.05 vs. anti-miR-126 alone group; cP <0.05 vs. pre-miR-126 alone group. Con, control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; PI, propidium iodide; RAPA, rapamycin.
×
Discussion
The natural product EGCG is the major polyphenolic constituent found in green tea. Studies suggest that EGCG is related to the potential health benefits attributed to green tea consumption[23]. The anticancer activity of EGCG has been extensively explored in past years. Although it is demonstrated that EGCG can suppress proliferation of various tumor cells, to our knowledge, articles about the roles of EGCG in osteosarcoma are few. In the present study, we confirm that EGCG can suppress proliferation of osteosarcoma MG63 and U2OS cells in a concentration-dependent and time-dependent manner; and the inhibitory effects of 0.05 g/L EGCG on U2OS cells were roughly equivalent to 20 μM DDP. These results provide novel evidence supporting development of EGCG for prevention of cancer, especially osteosarcoma.
It is well known that dysregulation of miRs will promote the malignant progression of tumor. Emerging evidences show that miRs also play an important role in the chemoresistance of cancer[24] and interference of some crucial miRs will improve the therapeutic efficacy of chemotherapeutics[25]. miR-126 is a commonly discovered loss in various cancers and its downregulation will promote proliferation, invasion, and migration in tumors[21, 22, 26]. Here, we also found miR-126 was underexpressed in MG63 and U2OS cells (data not shown), consistent with the results obtained by Yang et al.[19]; in the report, it was discovered that a low level of miR-126 was expressed in osteosarcoma tissues and cell lines. In addition, we found that overexpression of miR-126 resulted in inhibition of proliferation and induction of apoptosis in osteosarcoma U2OS cells. These results further confirm that miR-126 acts as a tumor suppressor in osteosarcoma.
Studies showed that miR-126 could enhance the sensitivity of non-small-cell lung cancer to adriamycin and vincristine[21] and cervical cancer cells to bleomycin[22]. In our study, we found that overexpression of miR-126 could enhance the sensitivity of osteosarcoma U2OS cells to polyphenolic EGCG. Our results showed that overexpression of miR-126 significantly enhanced the inhibitory action of EGCG on U2OS cells. Subsequently, we further verified that miR-126 could promote EGCG-induced apoptosis in U2OS cells; and EGCG-induced G1 phase arrest in U2OS cells was not apparently affected by miR-126 levels due to miR-126 itself having no marked effects on the G1 phase proportion in U2OS. The role of miR-126 identified by us in osteosarcoma cells is consistent with its performance in gastric cancer cells, that miR-126 could induce its apoptotic death but had no effects on cell cycle[27]. It suggests that the mechanisms underlying EGCG suppressing the proliferation of osteosarcoma cells mainly involve its ability to induce apoptosis and cell cycle arrest in the G1 phase, and miR-126 sensitizes U2OS cells to EGCG mainly through promotion of apoptosis.
Anzeige
EGCG can protect against cancer by causing cell cycle arrest and inducing apoptosis[28]. It was found that EGCG could irreversibly induce cell cycle G1 phase arrest, ultimately leading to apoptotic cell death by upregulation of WAF1/p21, KIP1/p27, INK4a/p16, and INK4c/p18, and downregulation of cyclin D1, cyclin E, cdk2, cdk4, and cdk6, irrespective of p53 status, in prostate carcinoma cells[29]. Slightly unlike this, in leukemia cells, it was demonstrated that EGCG could increase the pre-G1 phase proportion and induce apoptosis by upregulation of p53, Bax and p21 and downregulation of Bcl-2alpha[30]. These protein molecules are potential targets of EGCG in osteosarcoma cells. And miR-126 is likely a promotor of apoptotic cell death in osteosarcoma cells by regulation of PLK2, PI3KR2, Crk[27], PI3K, Akt[31], and so on.
Our results illustrate the effects of miR-126 and EGCG on proliferation, apoptosis and cell cycle distribution. However, further studies are required to elucidate the specific molecular mechanisms underlying miR-126 promotion of EGCG-induced apoptosis in osteosarcoma U2OS cells.
Conclusions
In summary, miR-126 can enhance EGCG suppressing the proliferation of osteosarcoma cells through induction of apoptosis.
Acknowledgments
This work was supported by the independent exploration and innovation project of Central South University Doctoral Students (2013zzts096).
Anzeige
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The authors declare that they have no competing interests.
Authors’ contributions
CT designed the study and drafted the manuscript. LJ and AH did the experiments. XH and LJ collected and analyzed the data. All authors read and approved the final manuscript.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
